NewLimit
Blake Byers is a Co-Founder at NewLimit since January 2022, focusing on extending lifespans. As an Investor and Founder at Byers Capital since March 2021, Blake has invested in notable companies such as Neuralink, Culdesac, Vial, Benchling, and Freenome. Previously, Blake served as a General Partner at Google Ventures from April 2010 to March 2021, leading investments in 38 companies, with 10 going public, 7 being acquired, 17 remaining active, and 4 shutting down. Blake holds a Ph.D. in Bioengineering from Stanford University and has completed studies at Duke University.
This person is not in the org chart
This person is not in any teams
NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.